Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

O Abla, E Jacobsen, J Picarsic… - Blood, The Journal …, 2018 - ashpublications.org
Abstract Rosai-Dorfman-Destombes disease (RDD) is a rare non–Langerhans cell
histiocytosis characterized by accumulation of activated histiocytes within affected tissues …

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

G Goyal, ML Heaney, M Collin… - Blood, The Journal …, 2020 - ashpublications.org
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a
neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK …

Histiocytosis

JF Emile, F Cohen-Aubart, M Collin, S Fraitag, A Idbaih… - The Lancet, 2021 - thelancet.com
Histiocytoses constitute a heterogeneous group of rare disorders, characterised by
infiltration of almost any organ by myeloid cells with diverse macrophage or dendritic cell …

The clinical spectrum of Erdheim-Chester disease: an observational cohort study

JI Estrada-Veras, KJ O'Brien, LC Boyd… - Blood …, 2017 - ashpublications.org
Erdheim-Chester disease (ECD) is a rare, potentially fatal multiorgan myeloid neoplasm
occurring mainly in adults. The diagnosis is established by clinical, radiologic, and histologic …

Histiocytoses: emerging neoplasia behind inflammation

J Haroche, F Cohen-Aubart, BJ Rollins… - The Lancet …, 2017 - thelancet.com
Histiocytoses are disorders characterised by inflammation and the accumulation of cells
derived from the monocyte and macrophage lineages, which results in tissue damage …

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial

Y Ji, S Chen, J Zhou, K Yang, X Zhang… - Blood, The Journal …, 2022 - ashpublications.org
Abstract The Kasabach-Merritt phenomenon (KMP) in kaposiform hemangioendothelioma
(KHE) is characterized by life-threatening thrombocytopenia and consumptive coagulopathy …

Erdheim-chester disease

J Haroche, F Cohen-Aubart… - Blood, The Journal of the …, 2020 - ashpublications.org
Erdheim-Chester disease (ECD) is characterized by the infiltration of tissues by foamy
CD68+ CD1a− histiocytes, with 1500 known cases since 1930. Mutations activating the …

Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology

RS Go, E Jacobsen, R Baiocchi, I Buhtoiarov… - Journal of the National …, 2021 - jnccn.org
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers
of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders …

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis

A Aaroe, R Kurzrock, G Goyal, AM Goodman… - Blood …, 2023 - ashpublications.org
Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) are rare non-
Langerhans cell histiocytoses (non-LCHs), for which therapeutic options are limited. MAPK …

Erdheim–Chester disease: a rapidly evolving disease model

F Pegoraro, M Papo, V Maniscalco, F Charlotte… - Leukemia, 2020 - nature.com
Erdheim–Chester disease (ECD) is a rare non-Langerhans cell histiocytosis with a putative
neoplastic and inflammatory nature. The disease is driven by mutations in proto-oncogenes …